(Q44046103)

29 November 2017

Nephrotic syndrome and AA amyloidosis revealing adult-onset cryopyrin-associated periodic syndrome (English)

1 reference

cryopyrin-associated periodic syndrome

29 November 2017

0 references

1 reference

1 reference

R Enríquez

1

1 reference

29 November 2017

A E Sirvent

2

1 reference

29 November 2017

S Padilla

3

1 reference

29 November 2017

R Noguera-Pons

4

1 reference

29 November 2017

E Andrada

5

1 reference

29 November 2017

F Ardoy

6

1 reference

29 November 2017

I Millán

7

1 reference

29 November 2017

F Amorós

8

1 reference

29 November 2017

7 May 2013

1 reference

29 November 2017

1 reference

29 November 2017

35

1 reference

29 November 2017

5

1 reference

29 November 2017

738-741

1 reference

Cryopyrinopathies: update on pathogenesis and treatment.

29 November 2017

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

Current status of understanding the pathogenesis and management of patients with NOMID/CINCA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

Risk factors for severe Muckle-Wells syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

CIAS1 mutation in a patient with overlap between Muckle-Wells and chronic infantile neurological cutaneous and articular syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

NLRP3 E311K mutation in a large family with Muckle-Wells syndrome--description of a heterogeneous phenotype and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

Natural history and outcome in systemic AA amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

The NLRP3 inflammasome promotes renal inflammation and contributes to CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

Pharmacokinetics of anakinra in subjects with different levels of renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

Biologic drugs in autoinflammatory syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0886022X.2013.790300

10.3109/0886022X.2013.790300

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference